Nektar Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was MXN13,764 Mil.
During the past 12 months, Nektar Therapeutics's average Total Assets Growth Rate was 417.60% per year.
During the past 3 years, the average Total Assets Growth Rate was -44.80% per year.
During the past 5 years, the average Total Assets Growth Rate was -43.70% per year.
During the past 10 years, the average Total Assets Growth Rate was -16.20% per year.
During the past 13 years, Nektar Therapeutics's highest 3-Year average Total Assets Growth Rate was 94.80%. The lowest was -49.80%. And the median was 0.30%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Nektar Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Nektar Therapeutics Total Assets Related Terms
Nektar Therapeutics Total Assets Historical Data
* Premium members only.
The historical data trend for Nektar Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Nektar Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nektar Therapeutics (MEX:NKTR) has a Total Assets of MXN13,764 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Nektar Therapeutics and its competitors.
Is Nektar Therapeutics' Total Assets too high?
Nektar Therapeutics' current Total Assets is MXN13,764 Mil. Overall, Nektar Therapeutics has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Total Assets compare to OCUL and PVLA?
Nektar Therapeutics' Total Assets of MXN13,764 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Nektar Therapeutics and its competitors. Nektar Therapeutics's current Total Assets is MXN13,764 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Nektar Therapeutics (MEX:NKTR) has a current Total Assets of MXN13,764 Mil. The stock's GF Value™ is MXN131.57, compared to a current price of MXN1,584.15 — trading 1104% above its estimated fair value. The current Total Assets is MXN13,764 Mil. Nektar Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Nektar Therapeutics (MEX:NKTR), the current Total Assets is MXN13,764 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nektar Therapeutics (MEX:NKTR) Overvalued in 2026?
Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued.
The current stock price of MXN1,584.15 is trading 1104% above its estimated GF Value™ of MXN131.57.
Key valuation signals for MEX:NKTR:
Total Assets: MXN13,764 Mil
GF Value™: MXN131.57 vs. price of MXN1,584.15 (1104% above fair value)
No single metric tells the full story. See the MEX:NKTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
47GF Score
Get the complete analysis for MEX:NKTR
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NKTR has been successfully added to your 
